LONDON --(BUSINESS WIRE)--Jun. 28, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2021 results on Wednesday, July 28, 2021 at 1 p.m.   London time ( 8 a.m. Eastern Daylight Time ).

Company to launch OSPREY investigational device exemption clinical study in the U.S. LONDON --(BUSINESS WIRE)--Jun. 15, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has received approval from the U.S.

Additional local business closings to occur later this year LONDON --(BUSINESS WIRE)--Jun. 1, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has successfully completed the initial closing of the divestiture of its heart valve (HV)

LONDON --(BUSINESS WIRE)--May 13, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 8 a.m. Eastern Time .

LONDON --(BUSINESS WIRE)--Apr. 28, 2021-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021 . For the first quarter of 2021, worldwide sales from continuing operations were $247.6 million , an

LONDON --(BUSINESS WIRE)--Apr. 26, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Verily, a subsidiary of Alphabet focused on life sciences and healthcare, today announced that the first patient has been enrolled in their collaborative UNCOVER

Intuitive, optical-based technology system now available around the world LONDON --(BUSINESS WIRE)--Apr. 20, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for

300th patient randomized in ANTHEM-HFrEF pivotal study LONDON --(BUSINESS WIRE)--Apr. 19, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has randomized the 300th patient in the A uto n omic Regulation Th erapy to E nhance M

LONDON --(BUSINESS WIRE)--Mar. 25, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2021 results on Wednesday, April 28, 2021 at 12 p.m.   London time ( 7 a.m. Eastern Daylight Time ).

LONDON --(BUSINESS WIRE)--Feb. 24, 2021-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020 . For the fourth quarter of 2020, worldwide sales from continuing operations were $269.6

LONDON --(BUSINESS WIRE)--Jan. 20, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2020 results on Wednesday, February 24, 2021 at 1 p.m.   London time ( 8 a.m.